Table 2. Complications after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
| Clavien Dindo arm of study | |||
|---|---|---|---|
| Frequency | Mitomycin 40 mg via IPHC, n (%), n=61 | Oxaliplatin 200 mg/m2 via IPHC, n (%), n=60 | Total |
| 0 | 7 (11.5) | 1 (1.7) | 8 |
| I | 5 (8.20) | 14 (23.3) | 19 |
| II | 29 (47.5) | 25 (41.7) | 54 |
| III | 0 (0.00) | 1 (1.7) | 1 |
| IIIa | 9 (14.8) | 9 (15.0) | 18 |
| IIIb | 3 (4.9) | 4 (6.7) | 7 |
| IV | 1 (1.6) | 1 (1.7) | 2 |
| IVa | 4 (6.6) | 1 (1.7) | 5 |
| IVb | 1 (1.6) | 1 (1.7) | 2 |
| V | 1 (1.6) | 3 (5.0) | 6 |
IPHC, intraperitoneal hyperthermic chemotherapy.